Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials.

Fiche publication

Date publication

novembre 2024

Journal

Journal of autoimmunity

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Solitano V, Yuan Y, Singh S, Ma C, Nardone OM, Fiorino G, Acosta Felquer ML, Barra L, D'Agostino MA, Pope J, Peyrin-Biroulet L, Danese S, Jairath V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39509741

Résumé

Advanced combination treatment (ACT), defined as a combination of at least 2 biologic agents, a biologic agent and an oral small molecule, 2 oral small molecules drug with different mechanisms of action is a proposed strategy to improve outcomes in patients with immune-mediated inflammatory disease (IMID). We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ACT with monotherapy in patients with select IMIDs.